Latest News

Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

AGAH Annual Meeting 2014 Mitigating risks in early medicines development

January 2014

View Articles

A volunteer panel the size of a city...

November 2013

View Articles

Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

March 2013

Moxifloxacin is used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. A meal shortens the QT interval and in some instances it is desirable to use moxifloxacin after a meal which may affect PK or PD or both; however there is no published data.

View Articles

Joint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)

February 2013

View Articles

RPL presents further confirmation of the food effect on the QTc interval

November 2012

View Articles

Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies

November 2012

View Articles

Meet the experts

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology

December 8, 2025

In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.

JSCPT 2025

5 – 6 December 2025

Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.

View event

Low data variability

Exceptional ECG generation

Experts in cardiac safety

Our specialist services

サービス一覧

News

Stay up to date with the latest activity at Richmond Pharmacology

AGAH Annual Meeting 2014 Mitigating risks in early medicines development

A volunteer panel the size of a city...

Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

Joint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)

RPL presents further confirmation of the food effect on the QTc interval

Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies

Meet the experts

Careers at Richmond

Our Videos

Latest news

Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology

Events

JSCPT 2025

About us

Knowledge Base

Connect with us